Diseased or dysfunctional central nervous system glial cell populations

Central nervous system (CNS) glial cells, including astrocytes, microglia, and oligodendrocytes, are vital for maintaining neuronal health, providing metabolic support, and managing the brain's immune environment. In many CNS pathologies, these cells undergo phenotypic shifts into "diseased" or "dysfunctional" states, such as reactive astrogliosis or chronic microglial activation, which can drive neuroinflammation and neuronal death (Liddelow et al., 2017, Nature). For example, in Alzheimer's disease, microglia may fail to clear amyloid-beta plaques effectively while secreting pro-inflammatory cytokines that exacerbate damage (Glass et al., 2010, Cell). Similarly, in Multiple Sclerosis, the dysfunction or death of oligodendrocytes leads to demyelination and subsequent axonal loss (Franklin and Ffrench-Constant, 2008, Nature Reviews Neuroscience). Therapeutic interventions targeting these populations often focus on modulating specific signaling pathways, such as CSF1R for microglial modulation or S1P receptors for astrocyte stabilization, to revert cells to a homeostatic state. Monitoring the status of these cells in patients typically involves biomarkers like GFAP for astrocytes or TSPO imaging for microglial activation (Chen and Guilarte, 2008, Biomarkers).

Other names

Reactive gliaActivated microgliaReactive astrocytesDysfunctional oligodendrocytesGliosis-associated cells

Modulation of glial activation states, inhibition of pro-inflammatory signaling, or promotion of remyelination and metabolic support.